Patient population first: the strategy behind country decisions

Trial sponsors are under growing pressure to expand into new geographies and reach more patients. Selecting countries early is an essential part of this process, but as many development teams have discovered, it’s also where recruitment risk is locked in.

Recruitment problems rarely begin when sites start screening. More often, they can be traced back to much earlier decisions about where a study should run in the first place. That’s because, while a country may offer promising patient population numbers, investigator experience, site infrastructure, operational maturity, and the ability to deliver increasingly complex protocols can vary significantly, resulting in challenges that only emerge once a study is underway.

In this sponsored discussion, Rebecca Sayers, senior director, global head, site enablement solutions for IQVIA, sat down with pharmaphorum’s Deep Dive editor, Eloise McLennan, to explore how sponsors can move from static country lists to a more consultative patient solution strategy that brings feasibility, population insight, and site reality together much earlier in planning.

Drawing on global site intelligence and early engagement insight, the conversation explores how sponsors can mitigate recruitment and delivery risk upstream.

Watch the video today to hear how IQVIA is helping sponsors to test assumptions before countries are selected, identifying where patient populations, experienced investigators, and operational readiness truly align.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 88,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialisation of innovative medical treatments to help improve patient outcomes and population health worldwide.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analysing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviours and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.